Kalaris Therapeutics financials
$2.90+1.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$12.4M | -$11.8M | -$10.8M | -$12.7M | -$12.3M | -$10.4M |
| Net income | -$11.5M | -$10.9M | -$10.0M | -$11.9M | -$11.3M | -$10.2M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-0.48 | $-0.46 | $-0.51 | $-0.64 | $-0.61 | $-2.52 |
| EBITDA | -$12.4M | -$11.8M | -$10.8M | -$12.7M | -$12.3M | -$10.4M |
| Operating cash flow | -$11.0M | -$11.6M | -$7.1M | -$11.3M | -$12.5M | -$7.4M |
| Free cash flow | -$11.0M | -$11.6M | -$7.1M | -$11.5M | -$12.5M | -$7.4M |
| Diluted shares | 23.8M | 23.7M | 19.6M | 18.7M | 18.7M | 4.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $43.2M | $34.4M | $98.1M | $42.4M | $88.4M | $101.0M |
| Short-term investments | $50.4M | $62.8M | $19.9M | $34.6M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $99.5M | $109.8M | $121.7M | $81.2M | $92.8M | $103.1M |
| Total liabilities | $41.9M | $41.2M | $42.9M | $39.3M | $39.7M | $39.2M |
| Shareholders' equity | $57.7M | $68.6M | $78.8M | $41.9M | $53.1M | $63.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology